Voyager Therapeutics, Inc. (VYGR) Balance Sheet

The steady reduction in total assets suggests that the company is liquidating its resource base faster than it can replenish it through new partnership milestones. This trajectory implies that the current business model is not yet self-sustaining and remains heavily dependent on external capital injections.

While the current ratio of 8.42 appears superficially strong, it is heavily distorted by the lack of significant short-term liabilities rather than an abundance of liquid assets. Investors should monitor this cash position closely, as the current burn rate suggests a high probability of a capital raise in the near term.

The deepening deficit highlights the structural challenge of funding a high-cost biotechnology platform without a consistent commercial product. This trend suggests that shareholder value is being continuously pressured by the necessity of financing ongoing research through equity-dilutive activities.